论文部分内容阅读
Zatz 及其同事曾提出氯苯咪吲哚(mazindol)可能改善 Dachenne 型肌营养不良症(DMD)患者的肌肉功能。在英国已批准用于16岁以上的病态肥胖患者作短期治疗。Zatz 等报告1例同时患有先天性生长激素缺乏症的 DMD 患儿,其病情恶化较之其他 DMD 患儿(包括其家族的其他成员)没有那么迅速,推论生长激素(GH)对 DMD 患者的肌肉萎缩存在一种有害作用。有报告使用氯苯咪吲哚治疗 DMD,其原理是该药抑制了 GH 的分泌。然而,Baritussio 等却提出在过度肥胖的患者中氯苯咪吲哚不能抑制 GH 的释放。Sekiya 等则提出氯苯咪吲哚应用于正常对照组时甚至可起 GH 和其他垂体前叶激素释放因子的作用。
Zatz and colleagues have suggested that mazindol may improve muscle function in patients with Dachenne’s muscular dystrophy (DMD). In the United Kingdom has been approved for morbidly obese patients over the age of 16 for short-term treatment. Zatz et al. Reported 1 case of DMD with congenital growth hormone deficiency who did not have a worse condition than other DMD children, including other members of his family, and concluded that growth hormone (GH) Muscle atrophy exists a harmful effect. The use of clomidazole in the treatment of DMD has been reported on the principle that it inhibits the secretion of GH. However, Baritussio et al. Suggest that clomidol can not inhibit the release of GH in over-obese patients. Sekiya et al. Suggested that clindamind could act as GH and other pituitary hormone releasing factors even when used in normal controls.